- Home
- AU vs ONC Comparison
AU vs ONC Comparison
Compare AU & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AU | ONC |
|---|---|---|
| Founded | 1944 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 34.8B |
| IPO Year | 1972 | N/A |
Fundamental Metrics
Financial Performance| Metric | AU | ONC |
|---|---|---|
| Price | $83.07 | $330.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $63.67 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 2.9M | 327.4K |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ 237.48 | N/A |
| EPS | ★ 4.53 | 0.58 |
| Revenue | ★ $8,575,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $70.41 | $35.34 |
| Revenue Next Year | $11.47 | $22.45 |
| P/E Ratio | ★ $18.84 | $563.08 |
| Revenue Growth | ★ 61.82 | 53.47 |
| 52 Week Low | $22.45 | $170.99 |
| 52 Week High | $89.19 | $385.22 |
Technical Indicators
Market Signals| Indicator | AU | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 45.89 |
| Support Level | $83.51 | $322.41 |
| Resistance Level | $86.52 | $345.58 |
| Average True Range (ATR) | 3.71 | 14.27 |
| MACD | 0.31 | -3.06 |
| Stochastic Oscillator | 51.73 | 13.37 |
Price Performance
Historical ComparisonAbout AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.